ACM
LXEO icon

Aquatic Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Aquatic Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,085
Closed -$10.8K – 1627
2025
Q4 		$10.8K Buy
+1,085
New +$9.9K ﹤0.01% 1332

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Aquatic Capital Management's LXEO Position: Q1 2026 in Review

Aquatic Capital Management sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 1,085 shares — an estimated $10.8K sold.

Aquatic Capital Management first reported a position in LXEO in Q4 2025 and held it in 1 quarter. The position peaked at $10.8K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Aquatic Capital Management reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 1,085 Lexeo Therapeutics shares in Q1 2026, an estimated $10.8K.
  • Aquatic Capital Management first reported a position in Lexeo Therapeutics in Q4 2025 and held it in 1 quarter.
  • Aquatic Capital Management's Lexeo Therapeutics position peaked at $10.8K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Aquatic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.